Sofie H. Tolmeijer

582 total citations
14 papers, 285 citations indexed

About

Sofie H. Tolmeijer is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sofie H. Tolmeijer has authored 14 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cancer Research, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sofie H. Tolmeijer's work include Cancer Genomics and Diagnostics (7 papers), Prostate Cancer Treatment and Research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Sofie H. Tolmeijer is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Prostate Cancer Treatment and Research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Sofie H. Tolmeijer collaborates with scholars based in Netherlands, Canada and United States. Sofie H. Tolmeijer's co-authors include Yufei Xie, Annemarie H. Meijer, Marcel J. M. Schaaf, Niven Mehra, Marjolijn J. L. Ligtenberg, Sjoerd H. van der Burg, Ferenc A. Scheeren, Thorbald van Hall, Marjolein Sluijter and Koen A. Marijt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Sofie H. Tolmeijer

13 papers receiving 285 citations

Peers

Countries citing papers authored by Sofie H. Tolmeijer

Since Specialization

Citations

This map shows the geographic impact of Sofie H. Tolmeijer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie H. Tolmeijer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie H. Tolmeijer more than expected).

Fields of papers citing papers by Sofie H. Tolmeijer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie H. Tolmeijer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie H. Tolmeijer. The network helps show where Sofie H. Tolmeijer may publish in the future.

Co-authorship network of co-authors of Sofie H. Tolmeijer

This figure shows the co-authorship network connecting the top 25 collaborators of Sofie H. Tolmeijer. A scholar is included among the top collaborators of Sofie H. Tolmeijer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofie H. Tolmeijer. Sofie H. Tolmeijer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	2391P LuPARP: Phase I trial of [177Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) 2025 ·Annals of Oncology ·Simran Sandhu, (unknown), (unknown), Megan Crumbaker, (unknown), (unknown), Joanna Chan, Patricia Banks, Ryan Wallace, Anis Hamid, (unknown), Ramin Alipour, George Kong, (unknown), Ben Tran, Sofie H. Tolmeijer, (unknown), (unknown), (unknown), (unknown)	0
2	Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). 2024 ·Journal of Clinical Oncology ·Edmond M. Kwan, Michael S. Hofman, Sarah W.S. Ng, Louise Emmett, Shahneen Sandhu, James P Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, (unknown), Andrew M. Scott, Andrew Martin, Martin R. Stockler, (unknown), Matti Annala, Sofie H. Tolmeijer, Arun Azad, Ian D. Davis, Alexander W. Wyatt, (unknown)	5
3	1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE) 2024 ·Annals of Oncology ·Sofie H. Tolmeijer, Emily Kwan, (unknown), Anthony M. Joshua, (unknown), Megan Crumbaker, Anis Hamid, A. Antón, (unknown), (unknown), (unknown), (unknown), Nattakorn Dhiantravan, Narjess Ayati, Shivakumar Keerthikumar, David L. Goode, (unknown), Michael S. Hofman, (unknown), Simran Sandhu	1
4	Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter? 2023 ·Critical Reviews in Clinical Laboratory Sciences ·(unknown), Sofie H. Tolmeijer, Niven Mehra, Jack A. Schalken	5
5	Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer 2023 ·Clinical Cancer Research ·Sofie H. Tolmeijer, (unknown), Takayuki Sumiyoshi, Edmond M. Kwan, Sarah W.S. Ng, Matti Annala, (unknown), Cameron Herberts, (unknown), Paul Hamberg, Diederik M. Somford, Inge M. van Oort, Jack A. Schalken, Niven Mehra, Nielka P. van Erp, Alexander W. Wyatt	26
6	Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer 2023 ·European Urology Oncology ·Sofie H. Tolmeijer, Sandra van Wilpe, Maartje J. Geerlings, Daniel von Rhein, Tineke J. Smilde, (unknown), Harm Westdorp, (unknown), Irma M. Oving, (unknown), Antoine G. van der Heijden, Tom Hofste, Marjan M. Weiss, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	10
7	Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer 2022 ·Cancers ·(unknown), Maartje J. Geerlings, Daniel von Rhein, Sofie H. Tolmeijer, Marjan M. Weiss, Christian Gilissen, Tom Hofste, (unknown), Marcel J. R. Janssen, Heidi Rütten, Camiel Rosman, Rachel S. van der Post, Bastiaan Klarenbeek, Marjolijn J. L. Ligtenberg	17
8	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer. 2022 ·Journal of Clinical Oncology ·Sofie H. Tolmeijer, (unknown), Takayuki Sumiyoshi, Sarah W.S. Ng, Edmond M. Kwan, Matti Annala, Inge M. van Oort, Jack A. Schalken, Nielka P. van Erp, Alexander W. Wyatt, Niven Mehra	4
9	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity 2021 ·Cancers ·Sandra van Wilpe, Sofie H. Tolmeijer, Rutger H.T. Koornstra, I. Jolanda M. de Vries, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	39
10	LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma 2021 ·SHILAP Revista de lepidopterología ·Sandra van Wilpe, Sofie H. Tolmeijer, I. Jolanda M. de Vries, Rutger H.T. Koornstra, Niven Mehra	4
11	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma 2021 ·Cancers ·Sofie H. Tolmeijer, Rutger H.T. Koornstra, Jan Willem B. de Groot, Maartje J. Geerlings, (unknown), Marye J. Boers‐Sonderen, Jack A. Schalken, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	5
12	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer 2020 ·JCO Precision Oncology ·Sofie H. Tolmeijer, (unknown), Jack A. Schalken, Maartje J. Geerlings, Inge M. van Oort, Nielka P. van Erp, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra	22
13	Glucocorticoids inhibit macrophage differentiation towards a pro-inflammatory phenotype upon wounding without affecting their migration 2019 ·Disease Models & Mechanisms ·Yufei Xie, Sofie H. Tolmeijer, (unknown), (unknown), Annemarie H. Meijer, Marcel J. M. Schaaf	81
14	Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling 2019 ·Journal for ImmunoTherapy of Cancer ·Koen A. Marijt, Marjolein Sluijter, (unknown), Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg, Thorbald van Hall	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact